Guggenheim reiterated their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a research note released on Wednesday,Benzinga reports. They currently have a $84.00 price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback